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Editorial
Detection and determination of tumor biomarkers are made from 
tissue and blood collection. During the last decade new biological 
sources are feasible: circulating tumor cells and circulating nucleic 
acids. They are composing a new field named as liquid biopsy. The 
availability of next-generation sequencing and Digital-PCR among 
other techniques, led to the possibility of getting the most out of this 
“circulating material” that would mirror the genetic and epigenetic 
features of the tumor. 
It would allow the genetic profiling of a patient tumor, contributing 
to the personalized medicine, with a very little invasive method. 
Furthermore, it would provide the possibility of getting multiple serial 
samples. A liquid biopsy could represent a diagnostic tool as well as it 
would be suitable to provide prognosis and predictive information. It 
could also be an interesting tool to screen individuals at risk to develop 
certain disease. 
Circulating nucleic acids and tumor cells is a very old discovery 
and represents a late development. The first reference to circulating 
tumor cells (CTCs) is from 1869. An Australian resident physician 
reported a case of cancer in which cells, similar to those in the tumor, 
were seen in the blood following the patient death [1]. It was not until 
1948 when Mendel and Métais found circulating nucleic acids in 
blood, that light was shed again on this topic [2]. The years between 
1955 and 1965 showed increased interest in this field with many 
reports being published [3,4]. During the past ten years, CTCs have 
received enormous attention as new biomarkers and the subject of 
basic research. 
Among the immunomagnetic assays, based upon positive CTCs 
selection, the Cell Search method developed by Janssen Diagnostics, 
is already approved for clinical use in metastatic breast cancer patients 
[5,6]. A cut off point of 5 CTCs detected in this group of patients 
showed prognosis value in terms of Disease Free Survival and Overall 
Survival. Patients with less than 5 CTCs per 7.5 ml/blood, determined 
by applying the CTC-Chip, has a better prognosis [5,6]. Also among 
the immunomagnetic assays, but based on negative selection and close 
to be approved for clinical use, are the microfluidic chips named as 
CTC-Chip and CTC-iChip [5,6].
Circulating cell free DNA (ccfDNA) is not derived from CTCs. 
There is a discrepancy between the number of CTCs and the peripheral 
blood ccfDNA quantity. A single human cell contains 6 pg of DNA 
and there is a median of 17 ng of DNA per ml of plasma in advanced-
stage cancers; therefore, if CTCs were the primary source of cctDNA it 
would require over 2,000 cells per ml of plasma. In reality, there are on 
average, less than 10 CTCs per 7.5 ml of blood [1]. Everybody reading 
the current text has ccfDNA, it is just a matter of quantity. In average, 
healthy individuals could have 2-5 ng of ccfDNA increasing the 
concentration up to 10-1000 ng in metastatic cancer patients, having 
individuals that bear a chronic immflamatory disease, an intermediate 
concentration. As an example, Dr. Thierry´s group reported a median 
of 24.37 ng of ccfDNA per ml of plasma in a group of 229 coloretal 
carcinoma patients versus a median concentration of 4.76 ng/ml in a 
group of 109 healthy individuals analyzed [7]. The majority of studies 
that evaluate total plasma ccfDNA have been performed in solid 
malignant tumor patients [7-10]. Only during the last few years, studies 
in this regard, have been reported in onco-hematology patients with 
similar findings as in solid tumors [11-18]. More recently, exosomes 
and microvesicles have been reported as the most successful way of 
isolating DNA, RNA and protein simultaneously [19].
In normal physiological conditions, sources of ccfDNA are 
mainly the epithelial tissues with a high turnover rate such as the 
grastrointestinal tract, the bone marrow and the fetus in a pregnant 
woman. In a pathological scenario, a solid tumor, is a complex tissue 
comprising both malignant and non-malignant cells (the last including 
endothelial, stroma cells and the immune system cells) that contribute 
to the so called tumor derived ccfDNA. Thus, there are three types of 
circulating DNA origin to be considered in a cancer patient: malignant 
tumor cells, non-malignant tumor cells, as well as, non tumor cells 
(germline circulating DNA) [5-21]. 
Not just DNA and not only from blood. Cell free DNA can be 
isolated both from circulating fluids (whole blood, serum, plasma, 
lympha) as well as from non-circulating fluids (feces, urine, milk) and 
from pathological accumulated fluids such as ascites [22]. Extracellular 
DNA can also be isolated from cell culture supernatant. 
Different types of circulating nucleic acids can be isolated: DNA, 
RNA, small non-coding RNA (being the microRNAs the most deeply 
analyzed), long non-coding RNAs and telomerase activity can be 
determined. Circulating nucleic acids can be found in different forms 
such as apoptotic bodies, nucleosomes, exosomes and protein-lipid-
DNA complexes. This partially depends upon the mechanism of release 
that could be apoptosis, necrosis, or other cell death mechanisms [23-
26]. Also a considerable DNA amount can be found in circulation 
attached to platelets and bound to cell plasma membranes.
In the field of oncology, circulating DNA is bearing the genetic 
and the epigenetic alterations of the cells they come from. Mutations, 
microsatellite alterations, methylation patterns and copy number could 
be determined. Circulating DNA is found as small fragments (146 bp 
or close to a nucleosome) and it is most fragmented in cancer patients 
than the healthy population. This has now been confirmed by atomic 
microscopy.
Up to day, CTCs counting has prognosis value in metastatic breast 
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cancer (evidence level I) and prostate cancer (evidence level II). The 
isolation of ccfDNA from exosomes and microvesicles has prognosis 
value in cancer patients (evidence level III). Regarding circulating cell 
free nucleic acids, ccfDNA has also prognosis value (II-2), circulating 
cell free RNA (ccfRNA) has shown to be useful in monitoring response 
to therapy (III) and enhanced circulating microRNA levels have also 
shown prognostic value in preclinical studies (See Note).
CTCs and ccfDNA isolation and characterization would certainly 
improve the diagnosis, treatment decisions and therapy response 
monitoring in oncology patients. The minimal invasive procedure 
necessary to perform a liquid biopsy makes it an excellent source to 
investigate a panel of multiple prognosis and predictive biomarkers 
at the patient diagnosis time and along the entire follow-up period 
(during therapy and post-treatment). As mentioned before, the CTCs 
number represents a prognosis factor in metastatic breast cancer. It 
remains a field of intense research the cancer stem cells phenotypic 
heterogeneity and plasticity between a MET-Like (Mesenchymal-
Epithelial transition) and a EMT-Like (Epithelial-Mesenchymal 
transition) phenotypes, information of different cancer stem cell 
subsets and their low number in circulation
Current and future research in ccfDNA should concentrate efforts 
on tumor genotyping. Particularly considering that there is often 
no enough tissue after the pathology analysis to perform molecular 
studies, following a relapse when a biopsy is not feasible nor routine, 
keeping in mind that the primary tumor could have evolved during 
therapy acquiring new genetics and epigenetic alterations, differences 
between primary cells and metastasis mutations and drug resistance 
development. All these tumor biology aspects could be investigated 
more easily through a liquid biopsy. Other areas to concentrate on are 
therapy response evaluation, minimal residual disease monitoring and 
early tumor detection.
Although CTCs are already being used in numerous clinical trials, 
it is still a challenging dynamic field of translational research. Even-
though many issues regarding the detection and characterization of 
CTCs remain unknown, it continues to be a highly promising area. 
The evaluation of epigenetic alterations, circulating cell free RNA 
and microRNA as potential biomarkers are still in their early steps. 
There are promising results in breast cancer and rectal carcinoma. 
Exosomes and microvesicles, as cell free nucleic acid source, are also at 
an early stage but there will be a pharmacological exploitation. 
The analysis of tumor genetic alterations has traditionally been 
performed on tissue biopsy material. However, many tumors are 
difficult to biopsy, are accessible only using fine needle aspirates 
(obtaining a small sample of usable material), or are located either in 
unknown sites (We have to consider oncology patients with multiple 
metastasis bearing an unknown primary tumor), or in sites that are 
challenging and risky to access. The traditional methods for tumor 
assessment fail to capture the heterogeneity of the disease, especially 
during progression. The Liquid Biopsy can profoundly improve the 
way clinicians face these issues. The Liquid biopsy, with a simple blood 
drawn, can sample different parts of the disease, will provide a “fluid” 
picture of the tumor cells alterations, can be repeated as needed for 
effective monitoring, and samples the part of the tumor that is associated 
with metastatic events. As a more detailed picture of the mutations that 
drive oncogenesis emerges, new avenues for researchers, clinicians, 
and drug developers have opened up.
Note: Clinical evidence level: I: well designed, randomized and 
controlled. II-1: well designed, controlled and non-randomized studies. 
II-2: analytical control case study, more than a single enter or more 
than a single research group. III: Authorities´opinion in the field based 
on clinical experience, reports from experts committees.
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